Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors represent the standard of care in patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). The availability of several EGFR tyrosine kinase inhibitors approved for use in the first-line or later settings in N...

Descripción completa

Detalles Bibliográficos
Autores principales: Harvey, R Donald, Adams, Val R, Beardslee, Tyler, Medina, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448811/
https://www.ncbi.nlm.nih.gov/pubmed/32567494
http://dx.doi.org/10.1177/1078155220931926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448811/
https://www.ncbi.nlm.nih.gov/pubmed/32567494
http://dx.doi.org/10.1177/1078155220931926

Ejemplares similares